IAG’ Scientific Research Team Presenting at ASCO, American Society of Clinical Oncology, 1-5 June 2018, Chicago, USA
IAG’s scientific research team are presenting at the American Society of Clinical Oncology, ASCO, in Chicago, USA from June 1-5, 2018. The team will discuss the challenges biotech companies face in oncology trials and explore IAG’s novel strategies to include advanced imaging biomarkers in the clinical development process. During ASCO, the IAG’ Team will present 4 abstracts focused on the strategic use of imaging in clinical research in oncology, including immuno-oncology, neuro-oncology, renal cancer and solid tumors.
The 2 posters to be presented and 4 abstracts were accepted:
ASSESSING DCE-MRI AND DWI AS TREATMENT RESPONSE BIOMARKERS AFTER SABR FOR PRIMARY RENAL CELL CARCINOMA, Hayley Reynolds, Bimal Parameswaran, Mary Finnegan, Diana Roettger, Eddie Lau, Tomas Kron, Mark Shaw, Sarat Chander, and Shankar Siva, American Society of Clinical Oncology (ASCO), 2018
Assessment of treatment response for renal cell carcinoma (RCC) is typically carried out using anatomical CT sized-based RECIST 1.1 criteria. Recently, our group completed a prospective trial delivering stereotactic ablative body radiotherapy (SABR) to patients with, while assessing treatment efficacy using advanced MRI techniques and novel early treatment response biomarkers. The details will be presented at ASCO.
NON-INVASIVE IN VIVO PREDICTION OF TUMOUR GRADE AND IDH MUTATION STATUS IN GLIOMAS USING DYNAMIC SUSCEPTIBILITY CONTRAST (DSC) PERFUSION- AND DIFFUSION-WEIGHTED MRI. Sotirios Bisdas, Cristiana Tisca, Carole Sudre, Eser Sanverdi, Diana Roettger, Jorge M Cardoso, American Society of Clinical Oncology (ASCO), 2018
In this study, we investigated the relevance of texture and statistical features extracted from perfusion and diffusion MRI parametric maps (PMs) to discriminate between WHO grades and IDH mutation status in gliomas to determine if such novel assessment may enhance tumour grading, improving patient selection for specific treatment options.
THE ROLE OF DIFFUSION TENSOR IMAGING FOR NON-INVASIVE IDH PHENOTYPING IN GLIOMAS, Diana Roettger, Jialin Yuan, Laura Mancini, Steffi Thust, Sebastian Brandner, Jeremy Rees, Andrew McEvoy, Sotirios Bisdas, American Society of Clinical Oncology (ASCO), 2018
This study explores whether diffusion tensor imaging (DTI) metrics can differentiate IDH mutation status in gliomas using 76 IDH mutant type and 27 IDH wild-type gliomas histopathologically verified with pre-treatment DTI. The details how the integration of the DTI metrics with demographic information may help to provide a non-invasive molecular stratification of the gliomas will be presented at ASCO.
THE ROLE OF DYNAMIC SUSCEPTIBILITY CONTRAST PERFUSION- WEIGHTED MRI IN THE ESTIMATION OF IDH MUTATION IN GLIOMAS, Sotirios Bisdas, Eser Sanverdi, Carole Sudre, Diana Roettger, Sebastian Brandner, Vasileios Katsaros, American Society of Clinical Oncology (ASCO), 2018
Dynamic Susceptibility Contrast Perfusion- Weighted Imaging (DSC – PWI) is a relatively recently established technique for gliomas staging and its diagnostic accuracy may benefit when using sophisticated image analysis algorithms. In this study, we aimed to investigate whether DSC – PWI, enhanced by texture analysis and machine learning, can stratify gliomas according to their IDH mutation status using a cohort of 208 patients. The details will be presented at ASCO.
IAG partners with biotechnology and pharmaceutical companies and supports clinical research programs with its scientific, operational and technological expertise.
IAG takes a holistic approach to biotech’s clinical development and brings together:
- An efficient purpose-built cloud-based system with embedded quality controls for trial data management (DYNAMIKA)
- Patented methodologies for quantitative assessment of treatment efficacy and safety
- Expertise to ensure regulatory compliance, targeted drug development and scientific credibility of your data
- Ensures that its bio-pharmaceutical clients gain the most benefits of early objective decision making on their treatment efficacy from utilizing advanced imaging techniques in their trials
Discover our risk assessment and management strategies to overcome the challenges in your oncology trial by contacting IAG at email@example.com
Founded in 1964, the American Society of Clinical Oncology is the world’s leading professional organization for physicians and oncology professionals caring for people with cancer. The 2018 Annual Meeting brings together more than 32,000 oncology professionals from around the world to discuss state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field. This year’s theme, Delivering Discoveries: Expanding the Reach of Precision Medicine, focuses on making precision medicine a reality by driving progress and expanding its reach so every patient has the chance to benefit. For more information on the conference click here.
IAG is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. Our dynamic Strategy, Trial Solutions and Bio-Partnering divisions work closely to meet critical needs of biotechnology companies: funding, clinical development and monetization of their assets. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed. www.ia-grp.com